[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100480546":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":45,"locations":52,"responsibleParty":77,"collaborators":79,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":12,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":12,"overallStatus":55,"whyStopped":12,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"University of Turin, Italy","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","Patients with central venous access (central umbilical venous catheter or epicutaneous cava catheter)",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Filter","EXPERIMENTAL","Patients with central venous access and in-line filters (central umbilical venous catheter or epicutaneous cava catheter)",[18],"Device: In-line filter",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DEVICE","In-line filter","All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.\n\nIn case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.\n\nIn case of drugs\u002Fsolutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed.",[14],[26,29,31,34,36,39,41],{"name":27,"affiliation":5,"role":28},"Francesco Cresi, PhD MD","STUDY_DIRECTOR",{"name":30,"affiliation":5,"role":28},"Alessandra Coscia, PhD MD",{"name":32,"affiliation":5,"role":33},"Elena Maggiora, MD","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":5,"role":33},"Cecilia Capetti, MD",{"name":37,"affiliation":38,"role":33},"Francesca De Matteis, RN","Città della salute e della Scienza di Torino",{"name":40,"affiliation":5,"role":33},"Martina Capitanio, MD",{"name":42,"affiliation":43,"role":44},"Fabio Mosca, Prof.","University of Milan, Italy","STUDY_CHAIR",[46,50],{"name":27,"role":47,"phone":48,"phoneExt":12,"email":49},"CONTACT","+390113135781","incas@cresi.org",{"name":32,"role":47,"phone":51,"phoneExt":12,"email":49},"+390113134437",[53],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Città della Salute e della Scienza","RECRUITING","Torino","Italia","10100","Italy","IT",{"type":62,"coordinates":63},"Point",[64,65],11.99138,44.88856,{"lat":65,"lon":64},[68,70,71,73,74,76],{"name":69,"role":47,"phone":12,"phoneExt":12,"email":12},"Francesco Cresi, MD, PhD",{"name":32,"role":47,"phone":12,"phoneExt":12,"email":12},{"name":35,"role":72,"phone":12,"phoneExt":12,"email":12},"SUB_INVESTIGATOR",{"name":40,"role":72,"phone":12,"phoneExt":12,"email":12},{"name":75,"role":72,"phone":12,"phoneExt":12,"email":12},"Francesca De Matteis",{"name":32,"role":33,"phone":12,"phoneExt":12,"email":12},{"type":33,"investigatorFullName":69,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Study Director",[80],{"name":81,"class":6},"Pall Corporation","100480546","intravenous-neonatal-central-access-safety-trial-100480546",false,"NCT05537389","Intravenous Neonatal Central Access Safety Trial","Central Lines Filtration in Newborns: a Multicenter Randomized Controlled Trial","INCAS","Inclusion Criteria:\n\n* All patients admitted to NICU with at least one central venous catheter\n\nExclusion Criteria:\n\n* Patients with peripheral venous catheter, patients with inflammatory episode at the time of enrollment","ALL","1 Hour","3 Months",{"count":94,"type":95},736,"ESTIMATED","INTERVENTIONAL",[98],"NA","Particulate contamination due to infusion therapy (administration of parenteral nutrition and medications) carries a potential health risk for infants in neonatal intensive care units (NICU).\n\nIn-line filtration is increasingly used in critically-ill infants but its benefits, by preventing micro-particle infusion in neonates, remain to be demonstrated.\n\nIn-line filters in the intravenous administration sets prevent the infusion of particles, which may reduce infectious complications.",[101,102],"Newborn Complication","Catheter Complications","2026-03-26",{"date":105,"type":106},"2026-03-30","ACTUAL",{"date":108,"type":106},"2023-01-01",{"date":110,"type":95},"2026-06-30",{"name":5,"class":6},1]